PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Clinical trials for PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New combo therapy aims to boost blood cells in bone marrow failure diseases
Disease control Recruiting nowThis study tests a combination of drugs to help people with aplastic anemia or low-risk myelodysplastic syndrome (MDS) who have dangerously low blood counts. The treatment includes horse anti-thymocyte globulin (hATG) and cyclosporine to calm the immune system, plus steroids and …
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
Immune boosting NK cells show promise in blood cancer trial
Disease control Recruiting nowThis study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Virus-Based therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Matched conditions: PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC